• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Investigating Differences in Pancreatic Ductal Adenocarcinoma Mutational Profiles Across Racial and Ethnic Groups: A Lack of Diversity Clouds the Picture.

作者信息

Li Judy, Geffner Adam, Cohen Noah A

机构信息

Division of Surgical Oncology, Department of Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

出版信息

Ann Surg Oncol. 2024 Oct;31(10):6361-6363. doi: 10.1245/s10434-024-15589-y. Epub 2024 Jun 10.

DOI:10.1245/s10434-024-15589-y
PMID:38858294
Abstract
摘要

相似文献

1
Investigating Differences in Pancreatic Ductal Adenocarcinoma Mutational Profiles Across Racial and Ethnic Groups: A Lack of Diversity Clouds the Picture.研究不同种族和族裔群体中胰腺导管腺癌突变谱的差异：缺乏多样性使情况变得模糊。
Ann Surg Oncol. 2024 Oct;31(10):6361-6363. doi: 10.1245/s10434-024-15589-y. Epub 2024 Jun 10.
2
The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.胰腺癌常见突变基因在肿瘤微环境调节中的作用
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820920969. doi: 10.1177/1533033820920969.
3
Heterogeneity of KRAS Mutations in Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌中KRAS突变的异质性
Pancreas. 2016 Sep;45(8):1111-4. doi: 10.1097/MPA.0000000000000624.
4
KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.KRAS 基因突变位于 12 或 13 密码子与胰腺导管腺癌的预后不良相关。
Pancreas. 2014 May;43(4):578-83. doi: 10.1097/MPA.0000000000000077.
5
Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report.遗传性弥漫性胃癌中的胰腺导管腺癌。病例报告。
Hum Pathol. 2012 Mar;43(3):457-61. doi: 10.1016/j.humpath.2011.06.008. Epub 2011 Oct 10.
6
Characterization of KRAS Mutation in Acinar and Langerhans Islet Cells of Patients With Pancreatic Ductal Adenocarcinoma.胰腺导管腺癌患者腺泡和胰岛细胞中KRAS突变的特征分析
Pancreas. 2016 Mar;45(3):337-41. doi: 10.1097/MPA.0000000000000478.
7
Evaluation of KRAS Mutation Status in a Patient With Concomitant Pancreatic Neuroendocrine Neoplasm and Intraductal Papillary Mucinous Neoplasm.一名同时患有胰腺神经内分泌肿瘤和导管内乳头状黏液性肿瘤患者的KRAS突变状态评估
Pancreas. 2019 May/Jun;48(5):e34-e35. doi: 10.1097/MPA.0000000000001286.
8
[Mutant K-ras gene in pathogenesis of pancreatic ductal adenocarcinoma].[胰腺导管腺癌发病机制中的突变型K-ras基因]
Zhonghua Bing Li Xue Za Zhi. 2012 Jan;41(1):62-5.
9
Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance.高危人群行胰腺癌监测的种族、民族和性别差异。
Cancer Prev Res (Phila). 2023 Jun 1;16(6):343-352. doi: 10.1158/1940-6207.CAPR-22-0529.
10
Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.胰腺导管腺癌中 K-ras、p53、c-erbB-2 和 DPC4 的基因改变及其与患者生存的相关性。
Pancreas. 2013 Mar;42(2):216-22. doi: 10.1097/MPA.0b013e31825b6ab0.

本文引用的文献

1
Annual report to the nation on the status of cancer, part 1: National cancer statistics.国家癌症报告：癌症统计数据 1. 全国癌症统计数据概览
Cancer. 2022 Dec 15;128(24):4251-4284. doi: 10.1002/cncr.34479. Epub 2022 Oct 27.
2
Health Care Disparities and the Future of Pancreatic Cancer Care.医疗保健差异与胰腺癌护理的未来。
Surg Oncol Clin N Am. 2021 Oct;30(4):759-771. doi: 10.1016/j.soc.2021.06.012.
3
The pancreatic cancer genome revisited.胰腺癌基因组再研究。
Nat Rev Gastroenterol Hepatol. 2021 Jul;18(7):469-481. doi: 10.1038/s41575-021-00463-z. Epub 2021 Jun 4.
4
Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.接受分子谱分析后接受匹配治疗的胰腺癌患者的总生存期：Know Your Tumor 登记试验的回顾性分析。
Lancet Oncol. 2020 Apr;21(4):508-518. doi: 10.1016/S1470-2045(20)30074-7. Epub 2020 Mar 2.
5
Disparities in Pancreatic Cancer Treatment and Outcomes.胰腺癌治疗与预后的差异。
Health Equity. 2019 Oct 29;3(1):532-540. doi: 10.1089/heq.2019.0057. eCollection 2019.
6
Closing the Disparity in Pancreatic Cancer Outcomes: A Closer Look at Nonmodifiable Factors and Their Potential Use in Treatment.缩小胰腺癌治疗结果的差距：深入探讨不可改变因素及其在治疗中的潜在应用
Pancreas. 2019 Feb;48(2):242-249. doi: 10.1097/MPA.0000000000001238.